Aopeng Medical’s Allvas System for Robotic-Assisted Endovascular Interventions Evaluated in Iliac, Thoracic, and Abdominal Anatomies

November 23, 2021—Aopeng Medical Technology Co., based in Shanghai, China, announced that the company’s Allvas endovascular intervention surgical robot completed the first-in-human clinical evaluation of robot-assisted peripheral artery intervention of an iliac artery. The procedure was performed by Professor Qing-Sheng Lu, MD, and his colleagues in the Department of Vascular Surgery at Shanghai Changhai Hospital of China Naval Medical University.

On September 21, the company announced that the team at Shanghai Changhai Hospital completed complex endovascular thoracic and abdominal aortic stent graft interventions with the Allvas in the first-in-human clinical trial of the robot-assisted intervention.

According to the company, the application of Allvas robotic-assisted technology enables precise evaluation of the target lesion and precise positioning through digital subtraction angiography. As a platform product, Aopeng’s endovascular interventional surgery robot covers the treatment of coronary, peripheral, neurologic, and vascular tumor diseases.

Aopeng stated that the robot provides a refined operation process to better ensure the safety of the procedure, reduce iatrogenic injury, and reduce the incidence of complications and post-operative reintervention rate.

Aopeng Medical expects that the endovascular interventional surgery robot will receive its registration certificate and start serving patients in 2023.